Factors contributing to an accelerated decline in pulmonary function in asthma

Allergology International

Volumn 63, Issue 2, 2014, Pages 181-188

  Kanemitsu, Yoshihiro ^a   Matsumoto, Hisako ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Asthma; Biomarker; Inhaled corticosteroids; Periostin; Pulmonary function decline

Indexed keywords

CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; TRANSCRIPTION FACTOR RUNX2; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

AIRWAY OBSTRUCTION; AIRWAY REMODELING; ASTHMA; DISEASE COURSE; DISEASE DURATION; EOSINOPHIL COUNT; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; HUMAN; LONG TERM CARE; LUNG FIBROBLAST; LUNG FUNCTION; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; REVIEW; SMOKING; TH2 CELL; BLOOD; COMPLICATION; INFLAMMATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; ASTHMA; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84901983871     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.13-RA-0670     Document Type: Review

References (66)

1. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999;104:1001-6.
2. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-200.
3. Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O'Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroiddependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
4. O'Byrne PM, Pedersen S, Busse WW et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006;129:1478-85.
5. Dijkstra A, Vonk JM, Jongepier H et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax 2006;61:105-10.
6. de Marco R, Marcon A, Jarvis D et al. Inhaled steroids are associated with reduced lung function decline in subjects with asthma with elevated total IgE. J Allergy Clin Immunol 2007;119:611-7.
7. Lange P, Scharling H, Ulrik CS, Vestbo J. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax 2006;61:100-4.
8. Niimi A, Matsumoto H, Amitani R et al. Effect of shortterm treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med 2004;116:725-31.
9. Matsumoto H, Niimi A, Takemura M et al. Long-term changes in airway-wall thickness on computed tomography in asthmatic patients. J Investig Allergol Clin Immunol 2011;21:113-9.
10. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Institute of Health, 2007.
11. Matsumoto H, Niimi A, Takemura M et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005;60:277-81.
12. Yamaguchi M, Niimi A, Matsumoto H et al. Sputum levels of transforming growth factor-beta1 in asthma: relation to clinical and computed tomography findings. J Investig Allergol Clin Immunol 2008;18:202-6.
13. Otsuka K, Matsumoto H, Niimi A et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration 2012;83:507-19.
14. Nagasaki T, Matsumoto H, Nakaji H et al. Smoking attenuates the age-related decrease in IgE levels and maintains eosinophilic inflammation. Clin Exp Allergy 2013;43: 608-15.
15. Tajiri T, Matsumoto H, Niimi A et al. Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma. PLoS One 2013;8:e65284.
16. Pizzichini E, Pizzichini MM, Efthimiadis A, Dolovich J, Hargreave FE. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. J Allergy Clin Immunol 1997;99:539-44.
17. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164: 744-8.
18. Broekema M, Volbeda F, Timens W et al. Airway eosinophilia in remission and progression of asthma: accumulation with a fast decline of FEV1. Respir Med 2010;104: 1254-62.
19. Shaw DE, Berry MA, Hargadon B et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007;132:1871-5.
20. Matsumoto H, Niimi A, Jinnai M et al. Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma. Respiration 2011;81:311-7.
21. van Veen IH, Ten Brinke A, Sterk PJ et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008;32:344-9.
22. Matsumoto H, Niimi A, Minakuchi M, Izumi T. Serum eosinophil cationic protein levels measured during exacerbation of asthma: characteristics of patients with low titres. Clin Exp Allergy 2001;31:637-43.
23. Takemura M, Matsumoto H, Niimi A et al. High sensitivity C-reactive protein in asthma. Eur Respir J 2006;27:908-12.
24. Szefler SJ, Wenzel S, Brown R et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129:S9-23.
25. Apostol GG, Jacobs DR, Tsai AW et al. Early life factors contribute to the decrease in lung function between ages 18 and 40: the Coronary Artery Risk Development in Young Adults study. Am J Respir Crit Care Med 2002;166: 166-72.
26. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994;150: 629-34.
27. Burrows B, Lebowitz MD, Barbee RA, Cline MG. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. J Allergy Clin Immunol 1991;88:870-7.
28. Cibella F, Cuttitta G, Bellia V et al. Lung function decline in bronchial asthma. Chest 2002;122:1944-8.
29. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007;132:1882-9.
30. Weiner P, Magadle R, Waizman J, Weiner M, Rabner M, Zamir D. Characteristics of asthma in the elderly. Eur Respir J 1998;12:564-8.
31. Parker AL, McCool FD. Pulmonary function characteristics in patients with different patterns of methacholine airway hyperresponsiveness. Chest 2002;121:1818-23.
32. Koh YI, Choi IS, Lim H. Airway responsiveness as a direct factor contributing to the dyspnoea perception in asthma. Respir Med 2001;95:464-70.
33. Rasmussen F, Taylor DR, Flannery EM et al. Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002;165:1480-8.
34. Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987; 70:171-9.
35. Van Schayck CP, Dompeling E, Van Herwaarden CL, Wever AM, Van Weel C. Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. Am Rev Respir Dis 1991;144:1297-301.
36. Rijcken B, Schouten JP, Xu X, Rosner B, Weiss ST. Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. Am J Respir Crit Care Med 1995;151:1377-82.
37. Postma DS, Lebowitz MD. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. Arch Intern Med 1995;155:1393-9.
38. Ulrik CS, Backer V. Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma. Eur Respir J 1999;14:892-6.
39. Bai TR, Vonk JM, Postma DS, Boezen HM. Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007;30:452-6.
40. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009;179:19-24.
41. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J 2000; 15:470-7.
42. Boulet LP, Lemière C, Archambault F, Carrier G, Descary MC, Deschesnes F. Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 2006;129:661-8.
43. James AL, Palmer LJ, Kicic E et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171:109-14.
44. Perret JL, Dharmage SC, Matheson MC et al. The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 2013;187:42-8.
45. Ulrik CS. Outcome of asthma: longitudinal changes in lung function. Eur Respir J 1999;13:904-18.
46. van Rensen EL, Sont JK, Evertse CE et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med 2005;172:837-41.
47. Pasternack R, Huhtala H, Karjalainen J. Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: a longitudinal analysis. J Allergy Clin Immunol 2005;116: 1123-8.
48. Imboden M, Bouzigon E, Curjuric I et al. Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol 2012;129: 1218-28.
49. Jongepier H, Boezen HM, Dijkstra A et al. Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004;34:757-60.
50. Dijkstra A, Howard TD, Vonk JM et al. Estrogen receptor 1 polymorphisms are associated with airway hyperresponsiveness and lung function decline, particularly in female subjects with asthma. J Allergy Clin Immunol 2006;117: 604-11.
51. Barton SJ, Koppelman GH, Vonk JM et al. PLAUR polymorphisms are associated with asthma, PLAUR levels, and lung function decline. J Allergy Clin Immunol 2009; 123:1391-400. e17.
52. Koppelman GH, Sayers I. Evidence of a genetic contribution to lung function decline in asthma. J Allergy Clin Immunol 2011;128:479-84.
53. Li X, Hawkins GA, Ampleford EJ et al. Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol 2013;132:313-20. e15.
54. Pauwels RA, Pedersen S, Busse WW et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003;361:1071-6.
55. Sidhu SS, Yuan S, Innes AL et al. Roles of epithelial cellderived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A 2010;107:14170-5.
56. Takayama G, Arima K, Kanaji T et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104.
57. Woodruff PG, Boushey HA, Dolganov GM et al. Genomewide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007;104:15858-63.
58. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54.
59. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-98.
60. Kanemitsu Y, Matsumoto H, Izuhara K et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305-12.
61. Okamoto M, Hoshino T, Kitasato Y et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 2011;37:1119-27.
62. Murphy AC, Proeschal A, Brightling CE et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax 2012;67:751-3.
63. Shirai T, Furuhashi K, Suda T, Chida K. Relationship of the asthma control test with pulmonary function and exhaled nitric oxide. Ann Allergy Asthma Immunol 2008; 101:608-13.
64. Lamblin C, Brichet A, Perez T, Darras J, Tonnel AB, Wallaert B. Long-term follow-up of pulmonary function in patients with nasal polyposis. Am J Respir Crit Care Med 2000;161:406-13.
65. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM; Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004;27: 752-7.
66. ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005;26:812-8.